FINWIRES · TerminalLIVE
FINWIRES

Teva Says AUSTEDO Improves Quality of Life in Huntington's Disease Study

By

Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals unit said Friday that a real-world study shows AUSTEDO tablets and AUSTEDO XR tablets improved quality of life for Huntington's disease chorea patients and their caregivers.

Huntington's disease is a fatal neurodegenerative disease characterized by uncontrollable movements as well as behavioral and/or psychological problems, the company said, adding that chorea is one of the most striking physical manifestations of the disease and occurs in about 90% of patients.

The survey data found that more than 68% of patients reported chorea affected their social life or emotional well-being, while up to 83% of caregivers reported disruptions to their own daily lives, the company said.

After treatment with AUSTEDO or AUSTEDO XR, 60% to 71% of patients reported improvements in quality of life due to better movement control, and as a result, caregivers also reported less impact on their daily lives, the company added.

Shares of Teva Pharmaceutical Industries rose nearly 1.4% in Friday's trading.

Price: $34.96, Change: $+0.53, Percent Change: +1.54%

Related Articles

Wire

Ainsworth Game Technology Chair Resigns; Shares Hit Over Eight-Year High

Ainsworth Game Technology (ASX:AGI) said that Non-Executive Chair Danny Gladstone has resigned with immediate effect following recent media reports concerning personal payments made to him more than eight years ago, according to a Friday filing with the Australian bourse.Gladstone said his resignation was intended to serve the company's best interests by allowing it to move beyond the distraction and focus on its strategic priorities, per the filing.Graeme Campbell has been appointed chair of the board, the filing added.The company's shares rose around 10% in recent Friday trade and earlier hit their highest level since April 2018.

$ASX:AGI
Wire

Wealthfront Fiscal Q1 Earnings Fall, Revenue Rises

Wealthfront (WLTH) reported fiscal Q1 earnings late Thursday of $0.07 per diluted share, down from $0.18 a year earlier.Analysts polled by FactSet expected EPS of $0.12.Revenue for the quarter ended April 30 was $90.5 million, up from $84.5 million a year earlier.Analysts expected $91.8 million.Shares of Wealthfront were down roughly 9% in after-hours activity.

$WLTH
Wire

Samsara Fiscal Q1 Non-GAAP Earnings, Revenue Rise; Shares Fall After Hours

Samsara (IOT) reported fiscal Q1 non-GAAP earnings late Thursday of $0.17 per diluted share, up from $0.11 a year earlier.Analysts polled by FactSet expected $0.13.Revenue in the three months ended May 2 rose to $478.8 million from $366.9 million a year earlier.Analysts expected $455.2 million.Samsara expects Q2 adjusted EPS of $0.15 to $0.16 on revenue of $482 million to $484 million.Analysts project EPS of $0.15 on revenue of $480.1 million.The company expects full-year adjusted EPS of $0.70 to $0.72 on revenue of $2.005 billion to $2.03 billion. Analysts project EPS of $0.68 on revenue of $1.97 billion.Samsara shares fell 3.2% in after-hours trading.

$IOT